Published on

Medicine – Non-Hodgkin Lymphomas (NHLs)

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignant lymphoid neoplasms characterised by clonal proliferation of B lymphocytes, T lymphocytes or natural killer (NK) cells.

They commonly arise in lymph nodes but may also originate in extranodal tissues, including the gastrointestinal tract, skin, bone marrow and central nervous system.

Approximately 85–90% of NHLs are of B-cell origin, although the distribution varies geographically and by lymphoma subtype.

Important Clinical Principle

Non-Hodgkin lymphoma is not a single disease. It comprises many distinct lymphoid malignancies with different growth rates, clinical presentations, molecular abnormalities, prognoses and treatment strategies.

1. Classification of Non-Hodgkin Lymphomas

NHLs are classified according to cellular origin, histological subtype and clinical behaviour.

Traditional classifications describe low-grade, intermediate-grade and high-grade lymphomas. Modern classification systems identify specific pathological and molecular entities, often grouped clinically as indolent or aggressive lymphomas.

Classification Clinical Behaviour Examples
Low-grade / Indolent Slowly progressive Follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma
Intermediate-grade / Aggressive Rapidly progressive Diffuse large B-cell lymphoma (DLBCL)
High-grade / Highly Aggressive Very rapid progression Burkitt lymphoma, certain high-grade B-cell lymphomas
Important Clarification: Histological grade and clinical aggressiveness are not interchangeable in every lymphoma subtype. Treatment should be based on the specific lymphoma diagnosis rather than grade alone.

2. Pathophysiology

NHL develops through acquired genetic and molecular abnormalities that promote uncontrolled lymphocyte proliferation and survival.

These abnormalities may interfere with normal cell-cycle regulation, apoptosis, lymphocyte differentiation and immune signalling.

Pathophysiology Flowchart

Genetic and Molecular Abnormalities Clonal Lymphocyte Expansion B cells / T cells / NK cells Lymphoid Tissue Infiltration Lymph nodes and extranodal organs Clinical Manifestations Lymphadenopathy B symptoms Extranodal involvement

Important Genetic Abnormalities

Genetic Abnormality Associated Lymphoma
t(14;18), BCL2Follicular lymphoma
MYC rearrangementBurkitt lymphoma
BCL6 abnormalitiesSome diffuse large B-cell lymphomas
t(11;14), CCND1 / cyclin D1Mantle cell lymphoma

3. Low-Grade (Indolent) Non-Hodgkin Lymphomas

Low-grade lymphomas generally follow a slowly progressive course and may remain asymptomatic for prolonged periods.

A. Clinical Presentation

Slowly progressive, painless peripheral lymphadenopathy is a common presenting feature.

  • Slowly enlarging lymph nodes.
  • Usually painless and rubbery lymphadenopathy.
  • Generalised lymphadenopathy may occur.
  • Symptoms may be absent for months or years.

B. Extranodal Involvement

Indolent lymphoma may involve the gastrointestinal tract, skin, bone marrow and other tissues.

C. B Symptoms

B symptoms include:

  • Unexplained fever above 38°C.
  • Drenching night sweats.
  • Unintentional weight loss exceeding 10% of body weight over six months.

B symptoms may be absent, especially in early or asymptomatic indolent disease.

D. Bone Marrow Involvement

Bone marrow infiltration is common in several indolent lymphoma subtypes.

It may cause:

  • Anaemia.
  • Neutropenia.
  • Thrombocytopenia.
  • Pancytopenia in advanced disease.

E. Splenomegaly

Splenomegaly may occur, particularly in advanced disease or specific lymphoma subtypes.

The traditional estimate of approximately 40% is not applicable to all low-grade NHLs because the frequency varies substantially by subtype and stage.

4. Intermediate- and High-Grade (Aggressive) Non-Hodgkin Lymphomas

Aggressive NHLs typically progress more rapidly than indolent lymphomas and may produce substantial tumour masses over a period of weeks.

A. Lymphadenopathy

The most common presentation is rapidly enlarging lymphadenopathy.

  • Rapidly growing lymph nodes.
  • Bulky lymphadenopathy.
  • Cervical, axillary, inguinal, mediastinal or abdominal lymph node involvement.
  • Compression of adjacent structures.

B. Extranodal Involvement

Extranodal involvement is common in some aggressive lymphoma subtypes.

Potential sites include:

  • Gastrointestinal tract.
  • Skin.
  • Bone marrow.
  • Paranasal sinuses.
  • Genitourinary tract.
  • Thyroid gland.
  • Bone.
  • Central nervous system.

C. Organ Enlargement

  • Splenomegaly.
  • Hepatomegaly.
  • Large abdominal masses.
  • Mediastinal masses.

D. B Symptoms

B symptoms occur more frequently in many aggressive lymphomas than in indolent lymphomas.

Fever, drenching night sweats and significant unintentional weight loss may accompany rapid tumour growth.

E. Other Clinical Manifestations

  • Fatigue and anorexia.
  • Abdominal pain or bowel obstruction.
  • Superior vena cava obstruction.
  • Neurological deficits due to CNS or spinal involvement.
  • Elevated lactate dehydrogenase (LDH).
  • Tumour lysis syndrome, particularly in rapidly proliferating disease.

5. Comparison: Indolent vs Aggressive NHL

Feature Indolent NHL Aggressive NHL
ProgressionSlowRapid
LymphadenopathySlowly enlarging, painlessRapidly enlarging, potentially bulky
B symptomsOften absent initiallyMore frequently present
Bone marrow involvementCommon in several subtypesVariable
Extranodal involvementMay occurCommon in some subtypes
Treatment urgencyObservation possible in selected casesUsually prompt treatment
Treatment outcomeOften responsive but prone to relapseSome subtypes potentially curable
Examination Point: Aggressive lymphomas may be curable with treatment, whereas many advanced indolent lymphomas follow a relapsing course despite long periods of disease control.

6. Diagnosis

A. Lymph Node Biopsy

Excisional lymph node biopsy is preferred when feasible because it preserves tissue architecture for histopathological assessment.

An adequate core needle biopsy may be used when excision is impractical.

Fine-needle aspiration alone is generally insufficient for initial definitive lymphoma classification.

B. Histopathology and Immunophenotyping

Biopsy specimens may undergo:

  • Histopathological examination.
  • Immunohistochemistry.
  • Flow cytometry when appropriate.
  • Cytogenetic and molecular investigations.

Important Immunophenotypic Markers

Marker Significance
CD20B-cell marker and therapeutic target
CD3T-cell marker
CD10Germinal-centre marker in selected B-cell lymphomas
CD5Expressed in certain B-cell and T-cell lymphomas
BCL2Anti-apoptotic protein
BCL6Germinal-centre-associated marker
Ki-67Proliferation index

C. Blood Investigations

  • Full blood count to identify anaemia and other cytopenias.
  • LDH as a marker of cell turnover and prognostic risk.
  • Renal function and electrolytes.
  • Liver function tests.
  • Uric acid.
  • Hepatitis B, hepatitis C and HIV testing when clinically appropriate, particularly before immunochemotherapy.

D. Imaging

CT and/or FDG-PET/CT are used to assess disease distribution and stage.

FDG-PET/CT is particularly useful in many FDG-avid lymphomas, including DLBCL.

E. Bone Marrow Examination

Bone marrow biopsy may be indicated in selected patients depending on lymphoma subtype, staging findings and whether the result would change management.

It is not universally required for every patient with NHL.

F. Cytogenetics and Molecular Testing

Testing may identify MYC, BCL2, BCL6 or other abnormalities relevant to lymphoma classification, prognosis and treatment planning.

Diagnostic Flowchart

Suspected NHL Lymphadenopathy / B symptoms / mass Tissue Biopsy Excision preferred when feasible Pathological Classification Immunophenotyping / molecular tests Staging Investigations CT / PET-CT ± marrow assessment Treatment Planning Subtype, stage, risk and fitness Guide individualised therapy

7. Ann Arbor / Lugano Staging

The Lugano classification is commonly used for staging NHL and incorporates the traditional Ann Arbor anatomical stages.

Stage Description
ISingle lymph node region or a single localized extranodal site
IITwo or more lymph node regions on the same side of the diaphragm
IIILymph node involvement on both sides of the diaphragm
IVDiffuse or disseminated extranodal involvement, such as liver or bone marrow

Staging must be interpreted alongside lymphoma subtype, tumour burden, symptoms and prognostic factors.

8. Management of Non-Hodgkin Lymphomas

Treatment depends on lymphoma subtype, stage, symptoms, tumour burden, patient fitness and molecular characteristics.

A. Indolent NHL

Selected asymptomatic patients with low tumour burden may undergo active surveillance (watch and wait).

When treatment is indicated, options may include:

  • Rituximab-based therapy for appropriate CD20-positive B-cell lymphomas.
  • Immunochemotherapy.
  • Local radiotherapy for selected localized disease.
  • Targeted treatments in appropriate subtypes.
  • Other systemic treatments for relapsed disease.

B. Aggressive B-Cell NHL

Aggressive lymphomas generally require prompt systemic treatment.

For many patients with diffuse large B-cell lymphoma, treatment may include:

  • R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone/prednisone.
  • Polatuzumab-R-CHP: An option for selected patients with DLBCL, depending on eligibility and local guidelines.

Other aggressive lymphoma subtypes require different treatment protocols.

C. Radiotherapy

Radiotherapy may be used for selected localized lymphomas, consolidation in certain settings or symptom relief.

D. Relapsed or Refractory NHL

Depending on subtype and eligibility, options may include:

  • Salvage chemotherapy.
  • Autologous stem cell transplantation.
  • CAR-T-cell therapy.
  • Bispecific antibodies.
  • Targeted agents and other immunotherapies.

E. Supportive Management

  • Infection prevention and treatment.
  • Management of anaemia and other cytopenias.
  • Nutritional support.
  • Monitoring for treatment-related toxicity.
  • Tumour lysis syndrome prophylaxis in high-risk patients.

Treatment Flowchart

Confirmed NHL Subtype and staging assessment Indolent NHL Usually slowly progressive Aggressive NHL Rapidly progressive Management Options Active surveillance Immunotherapy Chemo- / radiotherapy Management Options Prompt systemic therapy Subtype-specific regimen Potential curative intent Response and Follow-Up

9. Important Complications

  • Bone marrow failure and cytopenias.
  • Severe infections.
  • Organ compression by bulky lymphadenopathy.
  • Spinal cord compression.
  • CNS involvement in selected subtypes.
  • Tumour lysis syndrome.
  • Transformation of indolent lymphoma into aggressive lymphoma.
  • Treatment-related toxicity.

10. High-Yield Examination Summary

Feature Key Point
DefinitionClonal malignancy of B, T or NK lymphocytes
Most common cellular originB cells
Common presentationPainless lymphadenopathy
Indolent NHLSlowly progressive lymphadenopathy
Aggressive NHLRapidly enlarging, bulky lymphadenopathy
B symptomsFever, drenching night sweats, weight loss
Extranodal sitesGI tract, skin, bone marrow, CNS and others
DiagnosisTissue biopsy with immunophenotyping
StagingCT/PET-CT and Lugano classification
Common aggressive subtypeDiffuse large B-cell lymphoma
TreatmentSubtype-specific systemic therapy ± radiotherapy

11. Key Examination Pearls

  • NHL is a heterogeneous group of lymphoid malignancies rather than a single disease.
  • Most NHLs arise from B lymphocytes.
  • Painless lymphadenopathy is a classic presentation.
  • Indolent lymphomas usually grow slowly and may initially require observation only.
  • Aggressive lymphomas progress rapidly but may be curable with treatment.
  • B symptoms are unexplained fever, drenching night sweats and significant weight loss.
  • Extranodal involvement is an important feature of NHL.
  • Excisional biopsy is preferred when feasible for definitive diagnosis.
  • Immunophenotyping and molecular investigations determine lymphoma subtype.
  • Bone marrow biopsy is selectively performed rather than mandatory for every patient.
  • Treatment is guided by lymphoma subtype, stage, patient fitness and prognostic features.
Most Important Examination Point

Persistent painless lymphadenopathy, particularly when accompanied by B symptoms, splenomegaly or an extranodal mass, should raise suspicion of non-Hodgkin lymphoma. Definitive diagnosis requires adequate tissue biopsy and pathological classification before selecting treatment.

Clinical Note

Rapidly enlarging masses, airway compromise, neurological deficits, suspected spinal cord compression or tumour lysis syndrome require urgent medical assessment. NHL management should be individualised by a specialist haematology team.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments